Showing results (21-30 of 87) with videos related to
Sort By:
Pageof 9
Haematologica|December 3, 2009
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemiaSophie Park, Nicolas Chapuis, Jérôme Tamburini, et al.Cancer Chemotherapy and Pharmacology|October 1, 2015
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parametersZahra Ajgal, Nicolas Chapuis, George Emile, et al.Blood|September 20, 2007
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathwaysJerome Tamburini, Nicolas Chapuis, Valérie Bardet, et al.Oncotarget|February 4, 2016
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cellsJennifer Varin, Laury Poulain, Mikael Hivelin, et al.Blood Cancer Journal|November 16, 2018
Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosisSihem Tarfi, Véronique Harrivel, Florent Dumezy, et al.Annals of Intensive Care|July 17, 2016
Immature/total granulocyte ratio improves early prediction of neurological outcome after out-of-hospital cardiac arrest: the MyeloScore studyBertrand Sauneuf, Claire Bouffard, Edouard Cornet, et al.Pharmacological Research|July 6, 2016
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patientsAlicja Puszkiel, Mélanie White-Koning, Nicolas Dupin, et al.Journal of Clinical Medicine|October 14, 2022
Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 PatientsCamille Chenevier-Gobeaux, Morgane Ducastel, Jean-François Meritet, et al.Blood|May 22, 2009
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemiaJerome Tamburini, Alexa S Green, Valerie Bardet, et al.Oncogenesis|October 23, 2020
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemiaGodelieve Meunier, Rudy Birsen, Clarisse Cazelles, et al.Pageof 9